Probiotic Strains Market

Probiotic Strains Market Summary

The probiotic strains market is valued at USD 4.6 billion in 2026, up from USD 4.2 billion in 2025, as supplement and dairy brands are ordering more named strains. Strain ingredient revenue is on course to reach USD 12.0 billion by 2036 at a 10.1% CAGR.

FMI's estimate for 2026 rests on a shift in buying toward named strains with clear evidence rather than generic bacteria, as the NIH Office of Dietary Supplements states that clinical advice on probiotics needs to be strain-specific and tells shoppers to look for live counts at the end of shelf life [1]. Consumer use is also widening, which gives supplement brands a reason to place larger orders, and a NHANES-based study released by Michigan Medicine in September 2026 found that probiotic use among U.S. adults rose from 1.8% in 2009-2010 to 6.96% in 2021-2023 [2]. Supplier results confirm this pull, as Novonesis reported 10% organic growth in its Human Health business in 2025 [3], and ingredient demand is expected to keep pace with these trends through the forecast period.

Table 1: Market Size and Forecast for the Probiotic Strains Market (USD billion), 2025-2036

Market size and forecast	Value
2025 market size	USD 4.2 billion
Estimated market size in 2026	USD 4.6 billion
Projected market size by 2036	USD 12.0 billion
CAGR (2026-2036)	10.1%
Added revenue, 2026 to 2036	USD 7.4 billion

Key Market Trends & Insights

• Only 9.1% of product type sales come from Lactococcus lactis in 2026, yet this is the top share in a crowded field where no other strain group pulls clearly ahead.
• Cultured dairy products lead end-use application with 31.7% of sales in 2026, as yogurt and fermented milk plants buy fresh cultures for each production run.

Regional Highlights

The UK will post the quickest growth among the profiled countries, with a 13.1% CAGR over 2026 to 2036, while Japan at 12.7% and Germany at 10.8% take the next two places. South Korea follows at 8.6%, and the USA trails the group at 7.8%.

Market Evidence

Orders from supplement brands are climbing, as adult health and gut health supplements are winning more shelf space. BioGaia, a Swedish probiotic company, reported 2025 net sales of SEK 1,538.2 million, a 14% organic rise, while its Adult Health sales grew 22% organically to SEK 372.5 million [4]. This momentum continued into 2026, due to which BioGaia's first-half Adult Health sales rose 21% excluding currency effects to SEK 205.0 million [5]. Sales of adult-focused strains will therefore keep growing faster than the wider market during the forecast period.

Fresh fermentation lines are coming on stream at the biggest culture makers, which shows that they expect steady orders from dairy and supplement customers. Novonesis completed an expansion at West Allis, Wisconsin, in September 2026 that lifted fermentation capacity by about 66% and packaging capacity by 17% at a site making cheese and yogurt cultures [6]. Lallemand Health Solutions is also building a new formulation and blending area and a new encapsulation line at its Saint-Simon plant in France, which already produces more than 80 million sachets a year, backed by EUR 1.5 million in regional support announced in February 2026 [7]. 

Not every buyer group is ordering at the same pace, as some end markets are cooling while claim rules are tightening. Novonesis said its Human Health sales were EUR 251.1 million in the first half of 2026 with 4% organic growth, while its dietary supplement business was affected by a softening end-market in North America [8]. Claim rules add a second brake, which matters because the European Commission's 2007 guidance treats 'contains probiotics' as wording that implies a health benefit [9]. 

Table 2: Supporting Industry Indicators for the Probiotic Strains Market (mixed units), mixed years

Indicator	Data point	Why it matters	Source
Strain-specific advice (official rule)	NIH ODS says clinical recommendations need to be strain-specific and buyers should check live counts at end of shelf life (March 2025)	Buyers pay more for named, documented strains	[1]
U.S. adult probiotic use (NHANES)	1.8% in 2009-2010 to 6.96% in 2021-2023	Wider consumer use lifts supplement brand orders	[2]
Novonesis Human Health (2025 result)	EUR 494.8 million; 10% organic growth	Largest culture supplier's health unit growing near FMI pace	[3]
Novonesis Human Health (H1 2026 result)	EUR 251.1 million; 4% organic growth; North America supplements softer	Signals slower U.S. supplement demand	[8]
IFF Health & Biosciences (2025 result)	USD 2.28 billion sales; 3% comparable growth	Broad biosciences segment that includes probiotics	[13]
BioGaia net sales (2025 result)	SEK 1,538.2 million; 14% organic growth	Specialist strain brand growing faster than market	[4]
Novonesis West Allis expansion (capacity)	Fermentation capacity up about 66%, packaging up 17% (September 2026)	More culture supply for cultured dairy buyers	[6]
FDA preterm infant warning (rule)	One infant death and more than two dozen adverse events since 2018 (October 2023 warning)	Limits medical and infant uses	[12]
UK probiotic claims (rule)	General health claims must be paired with an authorised specific claim (CAP, August 2024)	Shapes UK marketing of probiotic products	[14]
Japan FFC rules (rule)	GMP for supplement-format FFC products enforceable from September 1, 2026	Raises quality checks for capsule and powder buyers	[15]
Korea functional ingredient rule (rule)	MFDS Notice No. 2026-33 English version posted August 13, 2026	Sets the route for strain recognition in Korea	[16]

Supplier Growth Benchmark Analysis

Supplier results help test FMI's growth path, since the FMI market grows by a calculated 9.5% from 2025 to 2026 (USD 4.2 billion to USD 4.6 billion) and then at a 10.1% CAGR. Novonesis Human Health grew 10% organically in 2025 [3], almost exactly in line with FMI's CAGR, while BioGaia grew 14% organically [4], or a calculated 3.9 percentage points above FMI's rate. IFF's Health & Biosciences segment grew only 3% on a comparable basis in 2025 [13], which reflects a broader mix of enzymes and food biosciences rather than probiotics alone.

Using Nutrition Insight's conversion of Novonesis Human Health sales to USD 584 million [3], this one business unit equals a calculated 13.9% of FMI's 2025 market value, although it also sells non-probiotic products such as human milk oligosaccharides. The 2026 data are more mixed, as Novonesis Human Health slowed to 4% organic growth in the first half [8] while BioGaia's Adult Health sales rose 21% excluding currency [5], which suggests that growth will come more from targeted adult and specialist strains than from broad U.S. supplement demand.

Table 3: Supplier Growth Benchmarks for the Probiotic Strains Market (mixed currencies and growth rates), 2025-2026, mixed periods

Metric	Value	Source
FMI market value 2025 / 2026	USD 4.2 billion / USD 4.6 billion	FMI
FMI implied growth 2025 to 2026	9.5%	Calculated
FMI CAGR 2026 to 2036	10.1%	FMI
Novonesis Human Health sales 2025	EUR 494.8 million (USD 584 million); 10% organic growth	[3]
Novonesis Human Health as share of FMI 2025 value	13.9%	Calculated
Novonesis Human Health H1 2026	EUR 251.1 million; 4% organic growth	[8]
IFF Health & Biosciences sales 2025	USD 2.28 billion; 3% comparable growth	[13]
BioGaia net sales 2025	SEK 1,538.2 million; 14% organic growth	[4]
BioGaia gap versus FMI CAGR	+3.9 percentage points	Calculated
BioGaia Adult Health H1 2026	SEK 205.0 million; 21% growth excluding currency	[5]
BioGaia Adult Health share of sales, H1 2026	25.2%	Calculated

Analyst Perspective

"Cultured Dairy Products will hold 31.7% of strain demand in 2026, yet the next wave of orders is set to come from strains that carry a clear, local claim. Suppliers that pair a named strain with country-ready evidence will win longer contracts than those selling on price per kilo."

- Nandini Roy Choudhury, Principal Analyst at Future Market Insights

How is the Probiotic Strains Market Segmented?

The probiotic strains market is split into product type, end-use application and region.

Product type covers Lactococcus lactis, Streptococcus, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium infantis, Lactobacillus rhamnosus, Pediococcus acidilactici, Bacillus coagulans, and Saccharomyces cerevisiae.
End-use application covers cultured dairy products, digestive health, bakery and confectionery, immune support, beverages, skincare, infant nutrition, vaginal health, and ice cream and frozen products.

Why Does Lactococcus lactis Lead the Probiotic Strains Market by Product Type?

Lactococcus lactis is set to hold 9.1% of market share by product type in 2026.

Lactococcus lactis holds a 9.1% share in 2026, as dairy makers already know this organism well from cheese and cultured milk production. It is also one of the best-studied lactic bacteria, as its full genome of 2,365,589 base pairs was published in Genome Research in 2001 [17], which gives buyers a strong technical base for quality checks. Large culture suppliers are adding output for this kind of bacteria, as Novonesis raised fermentation capacity at its West Allis culture site by about 66% in September 2026 [6]. Lactobacillus plantarum and Lactobacillus rhamnosus compete through strain-specific health evidence, Bifidobacterium infantis is tied to infant uses, Bacillus subtilis and Bacillus coagulans are chosen for hard processing conditions, and Saccharomyces cerevisiae offers a yeast option. The share spread is expected to stay wide, as no single organism group exceeds one-tenth of demand.

• In March 2024, Novonesis reported that Health Canada authorised claims for its CLEPIUS L. plantarum strain, including relief of irritable bowel syndrome symptoms in adults [18].

Why Do Cultured Dairy Products Lead the Probiotic Strains Market by End-Use Application?

Cultured dairy products account for 31.7% of end-use application demand in 2026.

Cultured dairy products account for 31.7% of demand in 2026, as yogurt and fermented milk plants need fresh starter cultures for every batch, which creates steady repeat orders. Suppliers are investing to serve these buyers, as the Novonesis West Allis site that makes cheese and yogurt cultures lifted packaging capacity by 17% alongside its fermentation upgrade [6]. Other applications are drawing new strain orders, as Probi and Nomura Dairy reported in May 2026 that an 8-week placebo-controlled study in Japanese adults supported LP299V in a carrot-juice format [19], while BioGaia's subsidiary expanded its skincare portfolio for babies and children with two new products a Gentle Balm to Milk Wash and a Soothing Face and Body Lotion in June 2026 [20]. Digestive health, immune support, infant nutrition and vaginal health are expected to gain share over the forecast period as claim-backed strains reach more supplement shelves.

• Cultured dairy will remain the largest end use at 31.7% in 2026, while the market as a whole grows at 10.1% CAGR to 2036.
• In December 2025, Lallemand Health Solutions announced that Proge Farm had extended its oral L. plantarum P17630 women's health licence to all European territories [21].

What are the Drivers, Restraints, and Opportunities in the Probiotic Strains Market?

Rising supplement use is lifting strain orders, while claim and safety rules slow launches; strain licensing for new uses opens fresh sales.

• Driver: More adults are taking probiotics, which lifts orders from supplement brands for documented strains.
• Restraint: Strict claim and safety rules, especially for infants and medical use, delay or block launches.
• Opportunity: Licensed strains with local claims can move into women's health, colon health and skincare.

Consumer uptake is the main driver, as probiotic use among U.S. adults nearly quadrupled from 1.8% in 2009-2010 to 6.96% in 2021-2023, a calculated 3.9-fold rise [2]. This wider use is reaching supplier sales, which is why BioGaia's Adult Health business grew 22% organically in 2025 [4]. Demand for strains used in adult digestive and immune health supplements is expected to keep rising through 2036.

Rules remain the main restraint, as the FDA said in October 2023 that probiotics sold for hospitalised preterm infants had been linked to one death and more than two dozen other adverse events since 2018 [12]. Marketing rules add more friction, while UK guidance from CAP in August 2024 says general health claims for probiotics must be paired with an authorised specific claim [14]. As a result, infant and medical launches are expected to take longer than food and supplement launches.

Licensing opens new routes to sale, as Lallemand's P17630 strain, now licensed across Europe following an agreement announced in December 2025, supports women's intimate health and is distributed under the Rosella brand [21]. Probi is also moving into new areas, which it did in November 2025 by adding sports nutrition and pet products built on strains such as LP299V and BLIS K12 [22]. Sales of strains for women's probiotic products, sports and pets will therefore add new demand beyond dairy over the forecast period.

Which Country CAGRs are Profiled in the Probiotic Strains Market?

Table 4: Country CAGRs for the Probiotic Strains Market (%), 2026-2036

Country	CAGR, 2026 to 2036
UK	13.1%
Japan	12.7%
Germany	10.8%
South Korea	8.6%
USA	7.8%

How do Country-level CAGRs Compare in the Probiotic Strains Market?

UK and Japan form the top band at 13.1% and 12.7%, as both markets are seeing new probiotic formats launched locally. Germany sits in a middle band at 10.8%, supported by EU-wide strain licensing but held back by EU claim rules. South Korea at 8.6% and the USA at 7.8% form the lower band, where large existing supplement bases and tighter rules on some uses keep growth slower.

• New probiotic supplements are launching in the UK first, which lifts strain orders and supports a 13.1% CAGR for the country.
• Japan will grow at 12.7% CAGR, as local food makers are adding probiotic strains to drinks and backing them with local studies.
• With EU-wide licences giving suppliers access but claim rules limiting label wording, Germany is set for a 10.8% CAGR.
• Strains entering South Korea must pass the national functional ingredient process, which slows new entries and holds growth to an 8.6% CAGR.
• A large but maturing supplement market is cooling in the USA, while infant and medical uses face strict review, leaving the country at a 7.8% CAGR.

The full report extends probiotic strains estimates to more than 25 countries and country groups across seven regions.

Country Outlook

• BioGaia named the UK as the first launch market for its colon-health probiotic BioGaia Colus in September 2026 [10], which signals early UK demand for clinical strains, and the UK is set to grow at 13.1% CAGR.
• In Japan, Probi and Nomura Dairy reported the first clinical study of LP299V in Japanese adults in May 2026 [19], while GMP rules for supplement-format FFC products became enforceable on September 1, 2026 [15], and Japan is projected to expand at 12.7% CAGR.
• German women's health formulations gained a new strain option in December 2025, when Lallemand gained rights to sell P17630 across all European territories [21], and Germany is expected to grow at 10.8% CAGR.
• South Korea's MFDS posted the English version of Notice No. 2026-33 on functional ingredient recognition in August 2026, noting that the Korean text remains official [16], and the country is forecast to grow at 8.6% CAGR.
• Novonesis reported a softening North American dietary supplement end-market in August 2026 [8], which explains the slower pace in the USA, where growth is forecast at 7.8% CAGR.

Who are the Leading Companies in the Probiotic Strains Market?

Chr. Hansen (now Novonesis), Lallemand, Probi, Danone, Yakult, Nestlé, BioGaia and DuPont are among the leading suppliers across merchant strain platforms, food and nutrition formulators and specialist platforms.

Competition is centred on a few merchant culture suppliers that own named strains and the evidence behind them. Chr. Hansen became part of Novonesis on January 29, 2024, creating a company with about 10,000 employees and around EUR 3.7 billion in combined revenue [23]. DuPont's former probiotic business moved to IFF when DuPont completed the Nutrition & Biosciences merger on February 1, 2021, receiving about USD 7.3 billion in cash [24]. Smaller specialists are changing ownership too, as Probi's shares were delisted from Nasdaq Stockholm with a last trading day of February 12, 2025 [25].

• Chr. Hansen Holding A/S (Novonesis), Lallemand Inc. and Probi AB (now a wholly owned subsidiary of Symrise AG following its 2025 delisting) form the merchant culture and strain platform group, selling named strains and licences to food and supplement makers.
• Among food and nutrition formulation owners, Danone S.A., Yakult Honsha Co., Ltd. and Nestlé S.A. use their own strains in finished dairy and nutrition products and shape buyer specifications.
• The specialist platforms and portfolio transitions group covers BioGaia AB, which develops branded L. reuteri products, and DuPont de Nemours, Inc., which is kept as a historical profile after its 2021 divestiture.

Competitive Benchmarking

Table 5: Competitive Benchmarking for the Probiotic Strains Market (qualitative ratings), 2026

Company	Strain Substantiation	Application Development	Commercial Route	Geographic Reach
Chr. Hansen Holding A/S (Novonesis)	High	High	High	Global; Canadian claim example
Danone S.A.	Medium	High	Medium	Global finished-product channels; merchant reach not established
DuPont de Nemours, Inc.	Unscored	Unscored	Unscored	Historical portfolio; divested to IFF in 2021
Yakult Honsha Co., Ltd.	High	High	High	Japan and overseas food channels
Nestlé S.A.	Medium	Medium	Medium	Infant nutrition channels; merchant reach not established
Lallemand Inc.	High	High	High	Europe, Asia, Americas
Probi AB	High	High	High	Over 40 markets; Japan partnership
BioGaia AB	High	Medium	Medium	Over 100 markets; UK first for new launch

Key Developments

• In January 2024, Novozymes and Chr. Hansen completed their combination to form Novonesis [23].
• In May 2025, Probi announced that Nomura Dairy had launched a My Flora fermented carrot drink with LP299V in Japan [11].
• In December 2025, Lallemand Health Solutions secured European rights for oral L. plantarum P17630 from Proge Farm [21].
• In February 2026, Lallemand announced new formulation, blending and encapsulation investments at its Saint-Simon plant [7].
• In September 2026, BioGaia announced BioGaia Colus with L. reuteri BG-R59, starting in the UK [10].

Key Players

Merchant Culture and Strain Platforms

• Chr. Hansen Holding A/S
• Lallemand Inc.
• Probi AB

Food and Nutrition Formulation Owners

• Danone S.A.
• Yakult Honsha Co., Ltd.
• Nestlé S.A.

Specialist Platforms and Portfolio Transitions

• BioGaia AB
• DuPont de Nemours, Inc.

Report Scope and Methodology

Table 6: Report Scope for the Probiotic Strains Market (descriptive), 2025-2036

Coverage field	Report scope
Market breakdown	Product Type; End-Use Application; Region
Quantitative units	USD Billion
Market definition	Revenue from live probiotic strain ingredients sold for the listed product types and end uses; finished food and supplement value, starter-only cultures, prebiotics and postbiotics are excluded.
Regions covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries covered	USA, UK, Germany, Japan and South Korea profiled; further countries organised under the regional taxonomy
Key companies profiled	Chr. Hansen Holding A/S; Danone S.A.; DuPont de Nemours, Inc.; Yakult Honsha Co., Ltd.; Nestlé S.A.; Lallemand Inc.; Probi AB; BioGaia AB
Forecast period	2026 to 2036
Approach	Ingredient-level revenue analysis with supply-side and application-side checks, base year 2025.

Research Methodology

Table 7: Research Methodology for the Probiotic Strains Market (descriptive), 2025-2036

Method	Approach
Primary research	Framework covering manufacturers, distributors, end users, procurement teams and experts on buying triggers, approvals, pricing and support.
Desk research	Regulator publications, company announcements and reports, scientific literature and trade press, limited to items published by October 2026.
Market sizing and forecasting	Strain ingredient revenue separated from finished-product turnover, with 2025 as base year and 2026 to 2036 as forecast period.
Data validation	Checks on values, periods, units, segment labels and country growth rates; double counting excluded.

Probiotic Strains Market by Segments

Probiotic Strains Market Segmented by Product Type

• Lactococcus lactis
• Streptococcus
• Lactobacillus plantarum
• Bacillus subtilis
• Bifidobacterium infantis
• Lactobacillus rhamnosus
• Pediococcus acidilactici
• Bacillus coagulans
• Saccharomyces Cerevisiae

Probiotic Strains Market Segmented by End-Use Application

• Cultured Dairy Products
• Digestive Health
• Bakery and Confectionary
• Immune Support
• Beverages
• Skincare (Cleaners, Toners, Serums, Moisturizers, Masks, Body lotion, etc.)
• Infant Nutrition
• Vaginal Microbiota/health
• Icecream and Frozen Products

Probiotic Strains Market Segmented by Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• [1] National Institutes of Health, Office of Dietary Supplements (2025, March 25). Probiotics: Fact Sheet for Health Professionals.
• [2] Michigan Medicine, University of Michigan (via Newswise) (2026, September 8). As probiotic use surges, microbiome-supportive food consumption stagnates.
• [3] Nutrition Insight (2026, February 26). Novonesis Human Health division achieves 10% organic sales growth in 2025.
• [4] BioGaia AB (2026, February 12). BioGaia AB: Year-end report January - December 2025.
• [5] BioGaia AB (2026, July 17). BioGaia AB: Interim Report January - June 2026.
• [6] Dairy Processing (2026, September 28). Novonesis fermentation capacity gets boost from expansion.
• [7] Lallemand Health Solutions (2026, February 11). The Saint-Simon Production Plant Continues to Invest.
• [8] Novonesis A/S (2026, August). H1 2026 Conference call slides.
• [9] European Commission, Standing Committee on the Food Chain and Animal Health (2007, December 14). Guidance on the implementation of Regulation No 1924/2006 on nutrition and health claims made on foods: Conclusions of the Standing Committee.
• [10] BioGaia AB (2026, September 9). BioGaia AB will launch a new clinically proven probiotic to support colon health.
• [11] Probi AB (2025, May 7). First-of-its-kind: Nomura Dairy and Probi introduce probiotic-enhanced carrot juice to Japan.
• [12] U.S. Food and Drug Administration (2023, October 26). FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants.
• [13] International Flavors & Fragrances Inc. (via Business Wire) (2026, February 11). IFF Reports Fourth Quarter and Full Year 2025 Results.
• [14] Committee of Advertising Practice (ASA/CAP) (2024, August 15). Food: Probiotic claims.
• [15] NutraIngredients (2024, July 8). Kobayashi knock-on effect: Japanese functional foods businesses legally bound to four new rules from Sep.
• [16] Ministry of Food and Drug Safety, Republic of Korea (2026, August 13). Regulation on Recognition of Functional Ingredient and of Standard·Specification for Health Functional Foods (Notice No. 2026-33).
• [17] Bolotin, A., Wincker, P., Mauger, S., et al., Genome Research (2001, May). The Complete Genome Sequence of the Lactic Acid Bacterium Lactococcus lactis ssp. lactis IL1403.
• [18] Novonesis A/S (2024, March 11). Novonesis probiotic strain receives health claim in Canada.
• [19] Probi AB (2026, May 27). Probi and Nomura Dairy achieve first clinical validation of LP299V in Japanese adults, advancing science-led probiotic innovation in Asia.
• [20] BioGaia AB (2026, June 18). BioGaia AB's subsidiary introduces a complete skincare routine for babies and children.
• [21] Lallemand Health Solutions (2025, December 9). Proge Farm granted to Lallemand Health Solutions the additional European license for oral L. plantarum PROGE P17630 following after-sales success.
• [22] Probi AB (2025, November 19). Probi expands its probiotic offering with two new areas: Sports & Active Nutrition and Pets.
• [23] Novonesis A/S (2024, January 29). Combination of Novozymes and Chr. Hansen now successfully completed.
• [24] DuPont de Nemours, Inc. (2021, February 1). DuPont Positioned as Premier Multi-Industrial Company Equipped for Growth and Value Creation following Completion of IFF and Nutrition & Biosciences Merger.
• [25] Probi AB (2025, February 3). Delisting of Probi.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• What are the probiotic strains market values in 2025, 2026 and 2036?
• What CAGR is the market expected to record between 2026 and 2036?
• Why does Lactococcus lactis lead the product type segment?
• Why do cultured dairy products lead end-use application demand?
• Which countries are growing fastest, and what is driving them?
• Which supplier results and capacity investments support the forecast?
• Which claim and safety rules limit launches in the USA, UK, EU, Japan and South Korea?
• Which companies lead merchant strain supply, and which mainly shape product specifications?